KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm. 2024;38(4):156-160 / www.klinickafarmakologie.cz 160 PŘEHLEDOVÉ ČLÁNKY Molekulární mechanismy a farmakologie kanabinoidů: od teorie k praxi macologic effects. Br J Clin Pharmacol. 2018;84(11):2468-2476. 46. Amendola G, Bocca B, Picardo V, et al. Toxicological aspects of cannabinoid, pesticide and metal levels detected in light Cannabis inflorescences grown in Italy. Food Chem Toxicol. 2021;156:112447. 47. Taylor A, Birkett JW. Pesticides in cannabis: A review of analytical and toxicological considerations. Drug Test Anal. 2020;12(2):180-190. 48. Volkow ND, Weiss SRB. Importance of a standard unit dose for cannabis research. Addiction. 2020;115(7): 1219-1221. 49. McDonagh MS, Morasco BJ, Wagner J, et al. Cannabis-Based Products for Chronic Pain : A Systematic Review. Ann Intern Med. 2022;175(8):1143-1153. 50. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456-2473. 51. Boehnke KF, Gangopadhyay S, Clauw DJ, et al. Qualifying Conditions Of Medical Cannabis License Holders In The United States. Health Aff (Millwood). 2019;38(2):295-302. 52. Slawek DE, Curtis SA, Arnsten JH, et al. Clinical Approaches to Cannabis: A Narrative Review. Med Clin North Am. 2022;106(1):131-152. 53. Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther. 2009;15(1):84-88. 54. Jetly R, Heber A, Fraser G, et al. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:585-588. 55. Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin Psychopharmacol. 2014;34(5):559-564. 56. Doppen M, Kung S, Maijers I, et al. Cannabis in Palliative Care: A Systematic Review of Current Evidence. J Pain Symptom Manage. 2022;64(5):e260-284. 57. MacDonald E, Farrah K. Medical Cannabis Use in Palliative Care: Review of Clinical Effectiveness and Guidelines – An Update [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019. cit. 29-11-2024. (CADTH Rapid Response Reports). Available from: http://www.ncbi.nlm.nih. gov/books/NBK551867/. 58. Hammond S, Erridge S, Mangal N, et al. The Effect of Cannabis-Based Medicine in the Treatment of Cachexia: A Systematic Review and Meta-Analysis. Cannabis Cannabinoid Res. 2021;6(6):474-487.
RkJQdWJsaXNoZXIy NDA4Mjc=